Summary

Market Overview
The Global Psychobiotics Market is projected to grow from USD 143.01 Million in 2025 to USD 173.67 Million by 2031 at a 3.29% CAGR. Psychobiotics comprise live microorganisms that provide mental health advantages to individuals by influencing the gut-brain connection when consumed in sufficient quantities. The primary catalysts for this market's growth include a heightened consumer understanding of the strong relationship between digestive health and mental wellness, coupled with the escalating rates of psychological issues like anxiety and stress. Additionally, the increasing body of scientific research validating the effectiveness of these specific microbial treatments accelerates market growth, as individuals increasingly look for natural, non-medication-based options to enhance their cognitive function and mood.
Nevertheless, the industry encounters significant hurdles due to intricate regulatory frameworks and the necessity for uniform clinical verification to back up specific health-related claims, potentially slowing down both product creation and consumer adoption. Although precise figures for the psychobiotics sector from industry groups are scarce for 2025, the wider probiotic supplements industry, which includes psychobiotics, shows robust engagement. Data from the International Probiotics Association indicates that the worldwide market for probiotic supplements reached a valuation of USD 9.0 billion in 2023.
Market Driver
The rising worldwide prevalence of mental health conditions acts as a major catalyst for the global psychobiotics market. The widespread increase in issues like depression, anxiety, and stress has generated a pressing need for innovative and successful treatment methods. Psychobiotics are standing out as an encouraging option as both medical systems and individuals actively pursue preventative and supplemental strategies for mental wellness. The magnitude of this issue is immense; the Institute for Health Metrics and Evaluation reported that 15% of the global population suffered from mental disorders in 2023, a staggering statistic that fuels financial backing for research and encourages the public to embrace natural mental health remedies.
Market growth is further accelerated by ongoing progress and validation in gut-brain axis studies. Continuous scientific explorations are shedding light on the complex, two-way communication networks linking the central nervous system with the gut microbiome, establishing a solid scientific base for psychobiotics. This growing comprehension encourages the creation of new products and reinforces the validity of health claims associated with psychobiotics. Highlighting this trend, a July 2025 Notice of Funding Opportunity from the National Institute of Environmental Health Sciences (NIEHS) on Grants.gov revealed a prospective $4,000,000 award for investigating the gut microbiome-brain connection, a financial injection that drives deeper study into product effectiveness and mechanisms. The massive economic toll of mental health problems further highlights the necessity of this market, as UN News reported in 2025, referencing the World Health Organization, that anxiety and depression exact an estimated annual cost of US$1 trillion on the global economy.
Market Challenge
A major obstacle facing the Global Psychobiotics Market is the intersection of complicated regulatory environments and the strict requirement for uniform clinical proof to support distinct health claims. Such regulatory barriers slow down the creation of new products and their introduction into the market. Because regulations are divided and vary widely across different regions, there is a lack of consistency in how psychobiotic items are classified, labeled, and evaluated for health claims. This absence of global alignment forces producers to modify their offerings to meet diverse national standards, thereby elevating the expenses associated with development and prolonging the time it takes to launch a product.
Additionally, market growth is directly hindered by the demanding need for solid clinical evidence to verify specific mental health advantages. Undertaking the essential, gold-standard human trials for new psychobiotic strains?particularly those aimed at intricate psychological effects?imposes substantial operational and financial strains on businesses. In the absence of definitive, scientifically backed claims endorsed by regulatory bodies, both medical professionals and consumers maintain a cautious stance, which in turn limits wider market penetration. The severity of this issue is highlighted by an August 2025 report for the International Probiotic Association Europe, which noted that the EFSA approved just one out of 355 evaluated probiotic health claims, demonstrating the intense difficulty of securing regulatory backing and its subsequent negative effect on industry innovation and product embrace.
Market Trends
A leading trend shaping the Global Psychobiotics Market is the rapid movement toward customized psychobiotic products. This strategy focuses on customizing microbial treatments to align with a person's unique gut microbiome, genetic background, and distinct mental health requirements. By stepping away from one-size-fits-all approaches, this targeted precision seeks to improve the effectiveness of treatments for issues such as anxiety and stress. Enhanced diagnostic tools play a vital role in this shift, building consumer confidence and paving the way for high-end products through a profound comprehension of individual gut-brain axis dynamics. Underscoring this continuous scientific backing, the Biocodex Microbiota Foundation declared a $50,000 USD research grant in April 2026 focused on "Harnessing the Gut Microbiome: Impacts on Health, Disease, Diagnosis and Therapeutics."
Another major trend in the market is the merging of psychobiotics with artificial intelligence and digital health technologies. This blend provides fresh opportunities for both interacting with consumers and developing new products. Machine learning and AI are becoming essential for in-depth microbiome evaluations, helping to pinpoint exact psychobiotic strains that offer mental health perks and to perfect product compositions. Furthermore, digital platforms enhance the user journey and broaden the market's scope by enabling remote monitoring of gut health, offering tailored suggestions, and boosting treatment compliance. These combined technologies are establishing data-centric networks that are set to transform how psychobiotics are researched, prescribed, and used, a shift supported by Google.org's January 2026 introduction of a $20 million AI for Science Fund aimed at advancing advanced scientific AI applications, including foundational models for the microbiome.

Key Market Players
* InnovixLabs
* Bened Biomedical Co., Ltd
* Nutrimmun GmbH
* Kerry Group Plc.
* Sabinsa Corporation
* Lallemand Health Solutions Inc.
* DuPont de Nemours, Inc.
* Uplift Food Pty Ltd.
* Nature's Bounty Co. Ltd.
* BioGaia Group

Report Scope
In this report, the Global Psychobiotics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

# Psychobiotics Market, By Psychotropic Agent
* Streptococcus
* Bifidobacterium
* Lactobacillus
* Clostridium
* Others
# Psychobiotics Market, By Form
* Powder
* Liquid/Fluid
* Tablets
* Others
# Psychobiotics Market, By Application
* Stress Management
* Mood Health & Mood Upliftment
* Depression
* Anxiety
* Sleep Problems
* Others
# Psychobiotics Market, By Distribution Channel
* Supermarkets and Hypermarkets
* Specialty Stores
* Online
* Others
# Psychobiotics Market, By Region
* North America
United States
Canada
Mexico
* Europe
France
United Kingdom
Italy
Germany
Spain
* Asia Pacific
China
India
Japan
Australia
South Korea
* South America
Brazil
Argentina
Colombia
* Middle East & Africa
South Africa
Saudi Arabia
UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Psychobiotics Market.
Available Customizations:
Global Psychobiotics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
* Detailed analysis and profiling of additional market players (up to five).

ページTOPに戻る

Table of Contents

1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Psychobiotics Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Psychotropic Agent (Streptococcus, Bifidobacterium, Lactobacillus, Clostridium, Others)
5.2.2. By Form (Powder, Liquid/Fluid, Tablets, Others)
5.2.3. By Application (Stress Management, Mood Health & Mood Upliftment, Depression, Anxiety, Sleep Problems, Others)
5.2.4. By Distribution Channel (Supermarkets and Hypermarkets, Specialty Stores, Online, Others)
5.2.5. By Region
5.2.6. By Company (2025)
5.3. Market Map
6. North America Psychobiotics Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Psychotropic Agent
6.2.2. By Form
6.2.3. By Application
6.2.4. By Distribution Channel
6.2.5. By Country
6.3. North America: Country Analysis
6.3.1. United States Psychobiotics Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Psychotropic Agent
6.3.1.2.2. By Form
6.3.1.2.3. By Application
6.3.1.2.4. By Distribution Channel
6.3.2. Canada Psychobiotics Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Psychotropic Agent
6.3.2.2.2. By Form
6.3.2.2.3. By Application
6.3.2.2.4. By Distribution Channel
6.3.3. Mexico Psychobiotics Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Psychotropic Agent
6.3.3.2.2. By Form
6.3.3.2.3. By Application
6.3.3.2.4. By Distribution Channel
7. Europe Psychobiotics Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Psychotropic Agent
7.2.2. By Form
7.2.3. By Application
7.2.4. By Distribution Channel
7.2.5. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Psychobiotics Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Psychotropic Agent
7.3.1.2.2. By Form
7.3.1.2.3. By Application
7.3.1.2.4. By Distribution Channel
7.3.2. France Psychobiotics Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Psychotropic Agent
7.3.2.2.2. By Form
7.3.2.2.3. By Application
7.3.2.2.4. By Distribution Channel
7.3.3. United Kingdom Psychobiotics Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Psychotropic Agent
7.3.3.2.2. By Form
7.3.3.2.3. By Application
7.3.3.2.4. By Distribution Channel
7.3.4. Italy Psychobiotics Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Psychotropic Agent
7.3.4.2.2. By Form
7.3.4.2.3. By Application
7.3.4.2.4. By Distribution Channel
7.3.5. Spain Psychobiotics Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Psychotropic Agent
7.3.5.2.2. By Form
7.3.5.2.3. By Application
7.3.5.2.4. By Distribution Channel
8. Asia Pacific Psychobiotics Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Psychotropic Agent
8.2.2. By Form
8.2.3. By Application
8.2.4. By Distribution Channel
8.2.5. By Country
8.3. Asia Pacific: Country Analysis
8.3.1. China Psychobiotics Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Psychotropic Agent
8.3.1.2.2. By Form
8.3.1.2.3. By Application
8.3.1.2.4. By Distribution Channel
8.3.2. India Psychobiotics Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Psychotropic Agent
8.3.2.2.2. By Form
8.3.2.2.3. By Application
8.3.2.2.4. By Distribution Channel
8.3.3. Japan Psychobiotics Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Psychotropic Agent
8.3.3.2.2. By Form
8.3.3.2.3. By Application
8.3.3.2.4. By Distribution Channel
8.3.4. South Korea Psychobiotics Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Psychotropic Agent
8.3.4.2.2. By Form
8.3.4.2.3. By Application
8.3.4.2.4. By Distribution Channel
8.3.5. Australia Psychobiotics Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Psychotropic Agent
8.3.5.2.2. By Form
8.3.5.2.3. By Application
8.3.5.2.4. By Distribution Channel
9. Middle East & Africa Psychobiotics Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Psychotropic Agent
9.2.2. By Form
9.2.3. By Application
9.2.4. By Distribution Channel
9.2.5. By Country
9.3. Middle East & Africa: Country Analysis
9.3.1. Saudi Arabia Psychobiotics Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Psychotropic Agent
9.3.1.2.2. By Form
9.3.1.2.3. By Application
9.3.1.2.4. By Distribution Channel
9.3.2. UAE Psychobiotics Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Psychotropic Agent
9.3.2.2.2. By Form
9.3.2.2.3. By Application
9.3.2.2.4. By Distribution Channel
9.3.3. South Africa Psychobiotics Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Psychotropic Agent
9.3.3.2.2. By Form
9.3.3.2.3. By Application
9.3.3.2.4. By Distribution Channel
10. South America Psychobiotics Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Psychotropic Agent
10.2.2. By Form
10.2.3. By Application
10.2.4. By Distribution Channel
10.2.5. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Psychobiotics Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Psychotropic Agent
10.3.1.2.2. By Form
10.3.1.2.3. By Application
10.3.1.2.4. By Distribution Channel
10.3.2. Colombia Psychobiotics Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Psychotropic Agent
10.3.2.2.2. By Form
10.3.2.2.3. By Application
10.3.2.2.4. By Distribution Channel
10.3.3. Argentina Psychobiotics Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Psychotropic Agent
10.3.3.2.2. By Form
10.3.3.2.3. By Application
10.3.3.2.4. By Distribution Channel
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. Global Psychobiotics Market: SWOT Analysis
14. Porter's Five Forces Analysis
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products
15. Competitive Landscape
15.1. InnovixLabs
15.1.1. Business Overview
15.1.2. Products & Services
15.1.3. Recent Developments
15.1.4. Key Personnel
15.1.5. SWOT Analysis
15.2. Bened Biomedical Co., Ltd
15.3. Nutrimmun GmbH
15.4. Kerry Group Plc.
15.5. Sabinsa Corporation
15.6. Lallemand Health Solutions Inc.
15.7. DuPont de Nemours, Inc.
15.8. Uplift Food Pty Ltd.
15.9. Nature's Bounty Co. Ltd.
15.10. BioGaia Group
16. Strategic Recommendations
17. About Us & Disclaimer